Objective: To observe the clinical efficacy and adverse reactions of ruxolitinib in the treatment of high risk primary myelofibrosis. Methods: In July 2017 and September,2 patients with primary myelofibrosis who were diagnosed as high risk in Qiqihar First Hospital were examined for blood routine,spleen and body weight changes before and after oral administration. Results: 2 patients were followed up for 5 ～ 7 months. The spleen was reduced,body weight increased and the consumptive symptoms disappeared. Con...
| 
推荐 
点击下列相关研究机构和相关文献作者，可以直接查到这些机构和作者被《中国知识资源总库》收录的其它文献，使您全面了解该机构和该作者的研究动态和历史。
